ArticleFrontiers in microbiology2026
From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Linezolid (Lzd) is a cornerstone for drug-resistant and complex tuberculosis (TB), but its utility is severely limited by hematological and neurological toxicities. Contezolid (Czd), a novel oxazolidinone, offers a potentially safer profile. However, real-world evidence remains limited. Objective: To evaluate the real-world effectiveness and safety of Czd in patients with complex TB, focusing on its role in managing Lzd toxicity through two distinct strategies: salvage therapy for Lzd-intolerant patients and proactive initiation in patients at high risk for Lzd-related adverse events. Methods: We conducted a retrospective study of TB patients treated with Czd-containing regimens. Patients were categorized into two groups: Group A switched from Lzd to Czd due to Lzd intolerance; Group B received Czd as initial treatment due to high risk of Lzd toxicity. Treatment outcomes, adverse events (AEs), and resolution of Lzd-related AEs after switching to Czd were analyzed. Results: All 31 patients in Group A experienced Lzd-related AEs (100%), with median onset of 45 days. Anemia was the most common AE (90%). After switching to Czd, significant recovery occurred in all AEs, with 52% achieving complete AE resolution. In Group B, no significant changes were observed. Treatment outcomes were excellent in both groups, with 100% clinical improvement and high sputum culture conversion rates (90% vs. 88%). Conclusion: Czd represented an effective salvage strategy for Lzd intolerance, significantly improving toxicity, ensuring therapeutic continuity, and suggesting preliminary evidence of maintained efficacy in complex TB. For patients at high risk of Lzd-related AEs, selecting Czd as initial therapy may prevent severe toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.